MGNX MacroGenics Inc: Bathi saben saham sajrone 12 wulan pungkasan

MacroGenics Corp (MGNX) - logo korporat

MacroGenics, Inc. (MGNX) is recognized for developing targeted antibodies that restore hope for oncology patients. However, the business faces risks of disrupted logistics chains and challenges in patent protection amid geopolitical pressure. Brand stability is confirmed by the trust of the global medical community. The market dynamics of the securities, with an EPS of 31.50, are presented below.

Bathi resik saben saham (EPS TTM) MacroGenics Corp (MGNX): kanggo periode 11.02.2024 - 16.11.2026

MGNX (macrogenics.com): rincian analitis lan laporan miturut indikator

- kuotasi saiki lan rata-rata prakiraan nilai:
Pambiji fundamental perusahaan:MGNX - MacroGenics
Sampel barang MacroGenics, Inc.

MacroGenics, Inc. (MGNX) is developing an immuno-oncology portfolio based on the DART and TRIDENT platforms, mitigating clinical-stage risks through strategic partnerships. By analyzing this annual EPS TTM chart, an investor assesses the rate of change in earnings per share over the last twelve months, allowing for a comparison of real business efficiency against market capitalization and the determination of the company's fundamental stability during periods of price consolidation.